Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder

Abraham Pavlotsky, Abraham Eidelman, Frida Barak, Haim Alon, Yoav Horn

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

We treated 47 patients with recurrent transitional cell carcinoma of the bladder with intravesical chemotherapy. Twenty milligrams of mitomycin C per treatment was introduced 7 days after transurethral resection (TUR) or diagnostic cystoscopy, and was repeated at 2‐week intervals for five times followed again by cystoscopy. Two more similar courses were administered for a total of 36 weeks. Clinical data revealed no toxicity‐related symptoms. Cystoscopic follow‐up showed a gradual decline in the presence of tumor to a complete response rate of 87.1% at 36 weeks. Thirteen patients who were previously treatment failures with other drugs responded to mitomycin C.

Original languageEnglish
Pages (from-to)9-11
Number of pages3
JournalJournal of Surgical Oncology
Volume41
Issue number1
DOIs
StatePublished - 1 Jan 1989
Externally publishedYes

Keywords

  • diagnostic cystoscopy
  • mitomycin C
  • superficial bladder cancer
  • transurethral resection

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder'. Together they form a unique fingerprint.

Cite this